However, the BRAFV600E mutation occurs in only 50%–70% of papillary thyroid carcinomas (PTCs), and BRAF mutations can distinguish between only benign neoplasm and malignant thyroid tumors at present, but there is a lack of evidence supporting the correlation between the BRAF mutation and the malignancy of thyroid cancer (13). Here, BRAF is linked to differentiated thyroid carcinoma.